Oxford vaccine to undergo new global trial after dosing error
Trials of the COVID-19 vaccine developed by Oxford University and AstraZeneca have raised eyebrows after it emerged that thousands of volunteers were given a lower dose by mistake.
For those who received the lower dose first, the vaccine’s efficacy was the highest at 90 per cent—while the results from giving volunteers two full doses of the vaccine showed a 62 per cent efficacy. Some 2,741 people received a half-dose of the vaccine followed by a full dose, the company had said. In a statement, Oxford later said that a difference in manufacturing processes led to later phases of the trial having a half-dose instead of a full one. After discussions with regulators, the decision was taken to push ahead with the two separate regimens.